• Order to parcel locker

    Order to parcel locker
  • easy pay

    easy pay
  • Reduced price
Histamine H4 receptor: a Novel Drug Target For Immunoregulation and Inflammation

Histamine H4 receptor: a Novel Drug Target For Immunoregulation and Inflammation

9788376560557
1,190.70 zł
1,131.16 zł Save 59.54 zł Tax included
Lowest price within 30 days before promotion: 1,131.16 zł
Quantity
Available in 7-14 days

  Delivery policy

Choose Paczkomat Inpost, Orlen Paczka, DPD or Poczta Polska. Click for more details

  Security policy

Pay with a quick bank transfer, payment card or cash on delivery. Click for more details

  Return policy

If you are a consumer, you can return the goods within 14 days. Click for more details

Description

H4 R is the newest member of the histamine receptor family, which was discovered about twelve years ago. It is considered a very promising drug target. The effort to improve the pharmacokinetic properties of the currently available H4 R ligands is reflected in a steadily growing number of scientific publications and patent applications. Preclinical data strongly confirms the need for novel potent H4 R ligands to explore their therapeutic value in allergy, inflammation, autoimmune disorders, and possibly, cancer.
Readers will be provided with extensive knowledge on histamine metabolism, as well as cellular histamine transport, storage and release, effects of histamine and histamine receptor ligands, with particular attention to the H4 R, on inflammatory cells including mast cells, basophils, eosinophils, neutrophils, macrophages, dendritic cells, and T cells. The present knowledge on the regulatory role of histamine and the therapeutic exploitation of histamine receptor ligands in atopic diseases, with emphasis on human and animal models of asthma, allergic dermatitis and pruritus are discussed.

Product Details
De Gruyter
99716
9788376560557
9788376560557

Data sheet

Publication date
2013
Issue number
1
Cover
hard cover
Pages count
368
Dimensions (mm)
170.00 x 240.00
Weight (g)
687
Comments (0)